Living Laboratory and Pontecorvo Pharmacogenomics Public Patient Involvement and Engagement Team
Published: 9 May 2024
The team recently held a public event
The Pontecorvo Pharmacogenomics Public Patient Involvement and Engagement Team and the Living Laboratory for Precision Medicine Pharmacogenomics group (Dr. Stefanie Lip-(PPIE Chair) , Dr. Iain Frater, Dr Linsay McCallum, Dr Louise Bennett, Ms Emma Johnson and Ms. Lauren Blackman) led by Professor Sandosh Padmanabhan (Pontecorvo Chair of Pharmacogenomics), organised a patient and public event at Queen Elizabeth University Hospital on March 26th and 27th, 2024 to understand the patient perspectives on the planned PHOENIX trial to establish the cost-effectiveness of pre-emptive pharmacogenomics in the NHS. This meeting brought together individuals who shared their personal encounters with adverse drug reactions and the challenges of managing multiple medications, highlighting the potential advantages of incorporating pharmacogenomics testing within the NHS framework. Throughout the event, participants not only acknowledged the benefits of such testing but also engaged in critical discussions concerning key issues including data privacy, the complexities of clinical trials, and the long-term viability of implementing pharmacogenomic strategies. Despite these challenges, there was a collective affirmation of the trial’s methodological soundness and the essential nature of its extended duration to ensure the production of dependable scientific data.
This collaborative effort signifies a substantial advance in the quest to integrate personalized medicine into broader healthcare practices, marking a milestone in the evolution of patient-centered pharmacological interventions spearheaded by SCMH and the Living Laboratory.
First published: 9 May 2024